$BNET
BION ENVIRONMENTAL TECHNOLOGIES INC

2020 Q4 Form 10-Q Financial Statement

#000107997320000945 Filed on November 09, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $291.7K $302.9K $320.2K
YoY Change -24.73% -5.42% -52.91%
% of Gross Profit
Research & Development $155.4K $90.99K $123.3K
YoY Change 35.76% -26.22% -27.34%
% of Gross Profit
Depreciation & Amortization $207.00 $207.00 $347.00
YoY Change -40.35% -40.35% -20.41%
% of Gross Profit
Operating Expenses $447.3K $394.1K $443.9K
YoY Change -10.96% -11.23% -47.66%
Operating Profit -$447.3K -$443.9K
YoY Change -10.96% -47.66%
Interest Expense $303.2K -$104.3K $117.6K
YoY Change 112.4% -188.72% 27.14%
% of Operating Profit
Other Income/Expense, Net -$303.2K -$117.6K
YoY Change 112.4% 27.14%
Pretax Income -$750.5K -$498.4K -$561.5K
YoY Change 16.34% -11.24% -40.27%
Income Tax
% Of Pretax Income
Net Earnings -$750.4K -$498.4K -$561.5K
YoY Change 16.34% -11.24% -40.3%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$24.05K -$16.17K -$20.42K
COMMON SHARES
Basic Shares Outstanding 30.15M 30.82M 27.41M
Diluted Shares Outstanding 31.19M 30.79M 27.47M

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $361.2K $336.1K $74.63K
YoY Change -23.02% 350.37% -58.54%
Cash & Equivalents $361.2K $336.1K $74.63K
Short-Term Investments
Other Short-Term Assets $5.350K $17.90K $12.83K
YoY Change 435.0% 39.52% 28.3%
Inventory
Prepaid Expenses $4.350K $16.90K $11.83K
Receivables
Other Receivables $1.000K
Total Short-Term Assets $366.5K $354.0K $87.46K
YoY Change -22.04% 304.76% -53.58%
LONG-TERM ASSETS
Property, Plant & Equipment $954.00 $1.161K $2.269K
YoY Change -50.36% -48.83% 124.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $954.00 $1.161K $2.269K
YoY Change -50.36% -48.83% 124.21%
TOTAL ASSETS
Total Short-Term Assets $366.5K $354.0K $87.46K
Total Long-Term Assets $954.00 $1.161K $2.269K
Total Assets $367.5K $355.2K $89.73K
YoY Change -22.16% 295.82% -52.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $600.0K $648.7K $790.1K
YoY Change -14.44% -17.9% 23.46%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $35.00K
YoY Change -100.0%
Long-Term Debt Due $9.755M $9.678M $9.374M
YoY Change 3.29% 3.24% 3.12%
Total Short-Term Liabilities $11.39M $11.21M $11.31M
YoY Change 6.31% -0.87% 9.91%
LONG-TERM LIABILITIES
Long-Term Debt $4.710M $4.646M $3.849M
YoY Change 4.14% 20.7% 8.12%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $4.710M $4.646M $3.849M
YoY Change 4.14% 20.7% 8.12%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.39M $11.21M $11.31M
Total Long-Term Liabilities $4.710M $4.646M $3.849M
Total Liabilities $16.10M $15.86M $15.16M
YoY Change 5.67% 4.61% 9.48%
SHAREHOLDERS EQUITY
Retained Earnings -$130.1M -$129.4M -$124.9M
YoY Change 3.65% 3.59% 1.86%
Common Stock $0.00 $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$15.78M -$15.54M -$15.12M
YoY Change
Total Liabilities & Shareholders Equity $367.5K $355.2K $89.73K
YoY Change -22.16% 295.82% -52.63%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$750.4K -$498.4K -$561.5K
YoY Change 16.34% -11.24% -40.3%
Depreciation, Depletion And Amortization $207.00 $207.00 $347.00
YoY Change -40.35% -40.35% -20.41%
Cash From Operating Activities -$281.4K -$247.2K -$151.2K
YoY Change -13.62% 63.54% -32.42%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 306.5K 22.50K 184.5K
YoY Change -57.45% -87.8% -51.21%
NET CHANGE
Cash From Operating Activities -281.4K -247.2K -151.2K
Cash From Investing Activities
Cash From Financing Activities 306.5K 22.50K 184.5K
Net Change In Cash 25.08K -224.7K 33.29K
YoY Change -93.64% -774.98% -78.44%
FREE CASH FLOW
Cash From Operating Activities -$281.4K -$247.2K -$151.2K
Capital Expenditures
Free Cash Flow -$247.2K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
bnet Common Stock Voting Rights Votes Per Share
CommonStockVotingRightsVotesPerShare
1
CY2020Q3 bnet Computers And Office Equipment Gross
ComputersAndOfficeEquipmentGross
171485
CY2020Q2 bnet Computers And Office Equipment Gross
ComputersAndOfficeEquipmentGross
171485
CY2020Q3 bnet Conversion Of Debt And Liabilities
ConversionOfDebtAndLiabilities
58325
CY2019Q3 bnet Conversion Of Debt And Liabilities
ConversionOfDebtAndLiabilities
CY2020Q3 bnet Deferred Compensation Consecutive Trading Days
DeferredCompensationConsecutiveTradingDays
P10D
CY2020Q3 bnet Deferred Compensation Conversion Days
DeferredCompensationConversionDays
P5D
CY2018 bnet Deferred Compensation Liability Amount Cancelled
DeferredCompensationLiabilityAmountCancelled
2404000
CY2013Q2 bnet Extension Of Exercise Period Annual Payment Per Option Or Warrant
ExtensionOfExercisePeriodAnnualPaymentPerOptionOrWarrant
0.05
CY2020Q3 bnet Interest Rate On Deferred Compensation
InterestRateOnDeferredCompensation
0.04
CY2020Q3 bnet Loans Payable Current Including Accrued Interest And Late Charges
LoansPayableCurrentIncludingAccruedInterestAndLateCharges
9656536
CY2020Q2 bnet Loans Payable Current Including Accrued Interest And Late Charges
LoansPayableCurrentIncludingAccruedInterestAndLateCharges
9585883
CY2020Q3 bnet Loans Payable To Affiliates
LoansPayableToAffiliates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 18pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">5</div></div><div style="display: inline; font-weight: bold;">. </div></div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">LOANS PAYABLE:</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Pennvest</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic; font: inherit;">PA1,</div> the Company's wholly-owned subsidiary, owes <div style="display: inline; font-style: italic; font: inherit;">$9,656,536</div> as of <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>under the terms of the Pennvest Loan related to the construction of the Kreider <div style="display: inline; font-style: italic; font: inherit;">1</div> System including accrued interest and late charges totaling <div style="display: inline; font-style: italic; font: inherit;">$1,902,536</div> as of <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020. </div>The terms of the Pennvest Loan provided for funding of up to <div style="display: inline; font-style: italic; font: inherit;">$7,754,000</div> which was to be repaid by interest-only payments for <div style="display: inline; font-style: italic; font: inherit;">three</div> years, followed by an additional <div style="display: inline; font-style: italic; font: inherit;">ten</div>-year amortization of principal. The Pennvest Loan accrues interest at <div style="display: inline; font-style: italic; font: inherit;">2.547%</div> per annum for years <div style="display: inline; font-style: italic; font: inherit;">1</div> through <div style="display: inline; font-style: italic; font: inherit;">5</div> and <div style="display: inline; font-style: italic; font: inherit;">3.184%</div> per annum for years <div style="display: inline; font-style: italic; font: inherit;">6</div> through maturity. The Pennvest Loan required minimum annual principal payments of approximately <div style="display: inline; font-style: italic; font: inherit;">$5,067,000</div> in fiscal years <div style="display: inline; font-style: italic; font: inherit;">2013</div> through <div style="display: inline; font-style: italic; font: inherit;">2020,</div> and <div style="display: inline; font-style: italic; font: inherit;">$819,000</div> in fiscal year <div style="display: inline; font-style: italic; font: inherit;">2021,</div> <div style="display: inline; font-style: italic; font: inherit;">$846,000</div> in fiscal year <div style="display: inline; font-style: italic; font: inherit;">2022,</div> <div style="display: inline; font-style: italic; font: inherit;">$873,000</div> in fiscal year <div style="display: inline; font-style: italic; font: inherit;">2023</div> and <div style="display: inline; font-style: italic; font: inherit;">$149,000</div> in fiscal year <div style="display: inline; font-style: italic; font: inherit;">2024.</div> The Pennvest Loan is collateralized by the Kreider <div style="display: inline; font-style: italic; font: inherit;">1</div> System and by a pledge of all revenues generated from Kreider <div style="display: inline; font-style: italic; font: inherit;">1</div> including, but <div style="display: inline; font-style: italic; font: inherit;">not</div> limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest is entitled to participate in the profits from Kreider <div style="display: inline; font-style: italic; font: inherit;">1</div> calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of <div style="display: inline; font-style: italic; font: inherit;">$61,722</div> for both the <div style="display: inline; font-style: italic; font: inherit;">three</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market to date, <div style="display: inline; font-style: italic; font: inherit;">PA1</div> commenced negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan. In the context of such negotiations, <div style="display: inline; font-style: italic; font: inherit;">PA1</div> has elected <div style="display: inline; font-style: italic; font: inherit;">not</div> to make interest payments to Pennvest on the Pennvest Loan since <div style="display: inline; font-style: italic; font: inherit;"> January 2013. </div>Additionally, the Company has <div style="display: inline; font-style: italic; font: inherit;">not</div> made any principal payments, which were to begin in fiscal <div style="display: inline; font-style: italic; font: inherit;">2013,</div> and, therefore, the Company has classified the Pennvest Loan as a current liability as of <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">On <div style="display: inline; font-style: italic; font: inherit;"> September 25, 2014, </div>Pennvest exercised its right to declare the Pennvest Loan in default and has accelerated the Pennvest Loan and demanded that <div style="display: inline; font-style: italic; font: inherit;">PA1</div> pay <div style="display: inline; font-style: italic; font: inherit;">$8,137,117</div> (principal, interest plus late charges) on or before <div style="display: inline; font-style: italic; font: inherit;"> October 24, 2014. </div><div style="display: inline; font-style: italic; font: inherit;">PA1</div> did <div style="display: inline; font-style: italic; font: inherit;">not</div> make the payment and does <div style="display: inline; font-style: italic; font: inherit;">not</div> have the resources to make the payment demanded by Pennvest. <div style="display: inline; font-style: italic; font: inherit;">PA1</div> has engaged in on/off discussions and negotiations with Pennvest concerning this matter but <div style="display: inline; font-style: italic; font: inherit;">no</div> such discussions/negotiations are currently active. As of the date of this report, <div style="display: inline; font-style: italic; font: inherit;">no</div> proposals (formal or informal) are under consideration and only sporadic communication has taken place regarding the matters involved in over <div style="display: inline; font-style: italic; font: inherit;">5</div> years. It is <div style="display: inline; font-style: italic; font: inherit;">not</div> possible at this date to predict the outcome of this matter given the extended period which has passed without resolution and the fact that the technology employed in the Kreider <div style="display: inline; font-style: italic; font: inherit;">1</div> system is now outdated. However, the Company believes that a loan modification agreement (coupled with an agreement regarding an update and restart of the full operation of Kreider <div style="display: inline; font-style: italic; font: inherit;">1</div> <div style="display: inline; font-style: italic; font: inherit;"> may </div>in the future be possible in conjunction with the Kreider <div style="display: inline; font-style: italic; font: inherit;">2</div> project, subject to the results of the negotiations with Pennvest and pending development of a more robust market for nutrient reductions in Pennsylvania. The Covid-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic has further increased uncertainties. <div style="display: inline; font-style: italic; font: inherit;">PA1</div> and Bion will continue to evaluate various options with regard to Kreider <div style="display: inline; font-style: italic; font: inherit;">1</div> over the next <div style="display: inline; font-style: italic; font: inherit;">six</div> to <div style="display: inline; font-style: italic; font: inherit;">twelve</div> months.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In connection with the Pennvest Loan financing documents, the Company provided a &#x2018;technology guaranty' regarding nutrient reduction performance of Kreider <div style="display: inline; font-style: italic; font: inherit;">1</div> which was structured to expire when Kreider <div style="display: inline; font-style: italic; font: inherit;">1's</div> nutrient reduction performance had been demonstrated. During <div style="display: inline; font-style: italic; font: inherit;"> August 2012 </div>the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider <div style="display: inline; font-style: italic; font: inherit;">1</div> System had surpassed the requisite performance criteria and that the Company's &#x2018;technology guaranty' was met. As a result, the Pennvest Loan is solely an obligation of <div style="display: inline; font-style: italic; font: inherit;">PA1.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">Paycheck Protection Program</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">During the year ended <div style="display: inline; font-style: italic; font: inherit;"> June 30, 2020, </div>the Company received proceeds from a loan in the amount of <div style="display: inline; font-style: italic; font: inherit;">$34,800</div> from Covenant Bank as the lender, pursuant to the Small Business Administration (&#x201c;SBA&#x201d;) Paycheck Protection Program (&#x201c;PPP&#x201d;) under the Coronavirus Aid, Relief, and Economic Security (&#x201c;CARES&#x201d;) Act. The loan is uncollateralized, has a fixed interest rate of <div style="display: inline; font-style: italic; font: inherit;">one</div> percent, a term of <div style="display: inline; font-style: italic; font: inherit;">two</div> years and the <div style="display: inline; font-style: italic; font: inherit;">first</div> payment is deferred for <div style="display: inline; font-style: italic; font: inherit;">six</div> months. Under the CARES Act, borrowers are eligible for forgiveness of principal and interest on PPP loans to the extent that the proceeds were used to cover eligible payroll costs, rent and utility costs over either an <div style="display: inline; font-style: italic; font: inherit;">8</div>- or <div style="display: inline; font-style: italic; font: inherit;">24</div>-week period after the loan was made. As of <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020, </div>the total PPP loan and accrued interest was <div style="display: inline; font-style: italic; font: inherit;">$34,939.</div> Management believes that the Company has met the conditions for full forgiveness of the PPP loan and will be applying for forgiveness once Covenant Bank and the SBA are ready to accept applications.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">&nbsp;&nbsp;</div></div></div>
CY2020Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q3 dei Entity Registrant Name
EntityRegistrantName
BION ENVIRONMENTAL TECHNOLOGIES INC
CY2020Q3 dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2020Q3 bnet Proceeds From The Sale Of Units
ProceedsFromTheSaleOfUnits
25000
CY2019Q3 bnet Proceeds From The Sale Of Units
ProceedsFromTheSaleOfUnits
159957
CY2019Q3 bnet Sale Of Units Value
SaleOfUnitsValue
159957
CY2020Q3 bnet Sale Of Units Value
SaleOfUnitsValue
25000
CY2020Q3 bnet Shares Held By Subsidiaries
SharesHeldBySubsidiaries
704309
CY2019Q3 bnet Shares Held By Subsidiaries
SharesHeldBySubsidiaries
704309
CY2019Q3 bnet Stock Issued During Period Value Commissions On Sale Of Units
StockIssuedDuringPeriodValueCommissionsOnSaleOfUnits
10496
CY2020Q3 bnet Stock Issued During Period Value Commissions On Sale Of Units
StockIssuedDuringPeriodValueCommissionsOnSaleOfUnits
2500
CY2020Q3 bnet Weighted Average Exercise Price For Outstanding Warrants
WeightedAverageExercisePriceForOutstandingWarrants
0.73
CY2020Q3 bnet Weighted Average Number Of Shares Issued During Period
WeightedAverageNumberOfSharesIssuedDuringPeriod
88938
CY2019Q3 bnet Weighted Average Number Of Shares Issued During Period
WeightedAverageNumberOfSharesIssuedDuringPeriod
102433
CY2020Q3 bnet Weighted Average Remaining Contractual Life For Outstanding Warrants
WeightedAverageRemainingContractualLifeForOutstandingWarrants
P3Y109D
CY2020Q3 bnet Working Capital
WorkingCapital
-10858000
CY2020Q3 dei Amendment Flag
AmendmentFlag
false
CY2020Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2020Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020Q3 dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
CY2020Q3 dei Document Type
DocumentType
10-Q
CY2020Q3 dei Entity Central Index Key
EntityCentralIndexKey
0000875729
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30154694
CY2020Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q3 dei Security12g Title
Security12gTitle
Common Stock, No Par Value
CY2020Q3 dei Trading Symbol
TradingSymbol
bnet
CY2020Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
648733
CY2020Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
628926
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2794464
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2794257
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
114350008
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
114266683
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2500
CY2020Q3 us-gaap Assets
Assets
355171
CY2020Q2 us-gaap Assets
Assets
571161
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
11043359
CY2020Q3 us-gaap Assets Current
AssetsCurrent
354010
CY2020Q2 us-gaap Assets Current
AssetsCurrent
569793
CY2020Q3 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
401470
CY2020Q2 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
401470
CY2020Q3 us-gaap Cash
Cash
336113
CY2020Q2 us-gaap Cash
Cash
560828
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
560828
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41335
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
336113
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
74627
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-224715
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
33292
CY2020Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
20600000
CY2020Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2020Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2020Q3 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
504650
CY2020Q2 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
504650
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31575656
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31409005
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28068688
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30871347
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30704696
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27364379
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
CY2020Q3 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">Concentrations of credit risk:</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times <div style="display: inline; font-style: italic; font: inherit;"> may </div>exceed federally insured limits. The Company has <div style="display: inline; font-style: italic; font: inherit;">not</div> experienced any losses on such accounts.</div></div></div></div></div>
CY2009Q1 us-gaap Construction Loan
ConstructionLoan
7750000
CY2020Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
4632167
CY2020Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
4595841
CY2020Q3 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
849941
CY2019Q3 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
1078134
CY2020Q2 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
778217
CY2020Q3 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1000
CY2020Q2 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1000
CY2020Q3 us-gaap Depreciation
Depreciation
207
CY2019Q3 us-gaap Depreciation
Depreciation
347
us-gaap Depreciation
Depreciation
207
us-gaap Depreciation
Depreciation
347
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
0
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
302877
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
320228
CY2020Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
40171
CY2019Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
74579
CY2020Q3 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
103901
CY2019Q3 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
196352
CY2020Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
8932
CY2019Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
3829
us-gaap Interest Expense
InterestExpense
104340
us-gaap Interest Expense
InterestExpense
117602
CY2020Q3 us-gaap Interest Paid Net
InterestPaidNet
CY2019Q3 us-gaap Interest Paid Net
InterestPaidNet
CY2020Q3 us-gaap Liabilities
Liabilities
15858216
CY2020Q2 us-gaap Liabilities
Liabilities
15659119
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
355171
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
571161
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
11212443
CY2020Q3 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
2222670
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2795625
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2795625
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1161
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1368
CY2020Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
2222670
CY2020Q3 us-gaap Minority Interest
MinorityInterest
41387
CY2020Q2 us-gaap Minority Interest
MinorityInterest
41902
CY2020Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22500
CY2019Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
184461
CY2020Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-247215
CY2019Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-151169
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-515
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-505
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-497897
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-560997
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-104340
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-117602
us-gaap Operating Expenses
OperatingExpenses
394072
us-gaap Operating Expenses
OperatingExpenses
443900
us-gaap Operating Income Loss
OperatingIncomeLoss
-394072
us-gaap Operating Income Loss
OperatingIncomeLoss
-443900
CY2020Q3 us-gaap Other Noncash Expense
OtherNoncashExpense
113350
CY2019Q3 us-gaap Other Noncash Expense
OtherNoncashExpense
126534
CY2020Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2500
CY2019Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
10496
CY2020Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
16897
CY2020Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7965
CY2020 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1584000
CY2019 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
897000
CY2020Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
25000
CY2020Q3 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
CY2019Q3 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
35000
CY2020 us-gaap Profit Loss
ProfitLoss
-4553000
CY2019 us-gaap Profit Loss
ProfitLoss
-2659000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-498412
CY2019Q3 us-gaap Profit Loss
ProfitLoss
-561502
us-gaap Profit Loss
ProfitLoss
-498412
us-gaap Profit Loss
ProfitLoss
-561502
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
90988
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
123325
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-129389790
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-128891893
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
CY2020Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2500
CY2019Q3 us-gaap Share Based Compensation
ShareBasedCompensation
16350
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
9511600
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.74
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9511600
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9511600
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.74
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.74
CY2020Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2020Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2020Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2020Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y73D
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y182D
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y73D
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
0
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
0
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
CY2020Q3 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Current
SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
35900
CY2020Q2 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Current
SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
35400
CY2020Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
CY2020Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
58325
CY2019Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
16350
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-15544432
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-15129860
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-14674598
CY2019Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-15070289
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-15087958
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-15503045
CY2020Q3 us-gaap Unsecured Debt Current
UnsecuredDebtCurrent
21333
CY2020Q2 us-gaap Unsecured Debt Current
UnsecuredDebtCurrent
14933
CY2020Q3 us-gaap Unsecured Long Term Debt
UnsecuredLongTermDebt
13606
CY2020Q2 us-gaap Unsecured Long Term Debt
UnsecuredLongTermDebt
19919
CY2020Q3 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">Use of estimates:</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In preparing the Company's consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div></div></div></div></div>
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30793634
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27466812
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30793634
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27466812

Files In Submission

Name View Source Status
0001079973-20-000945-index-headers.html Edgar Link pending
0001079973-20-000945-index.html Edgar Link pending
0001079973-20-000945.txt Edgar Link pending
0001079973-20-000945-xbrl.zip Edgar Link pending
bion_10q-093020.htm Edgar Link pending
bnet-20200930.xml Edgar Link completed
bnet-20200930.xsd Edgar Link pending
bnet-20200930_cal.xml Edgar Link unprocessable
bnet-20200930_def.xml Edgar Link unprocessable
bnet-20200930_lab.xml Edgar Link unprocessable
bnet-20200930_pre.xml Edgar Link unprocessable
ex31x1.htm Edgar Link pending
ex31x2.htm Edgar Link pending
ex32x1.htm Edgar Link pending
ex32x2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending